Fifth Third Bancorp Buys New Position in Kymera Therapeutics, Inc. $KYMR

Fifth Third Bancorp bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 51,238 shares of the company’s stock, valued at approximately $4,268,000.

Several other institutional investors also recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its position in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. boosted its position in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the period. Finally, Commodore Capital LP purchased a new position in Kymera Therapeutics in the 2nd quarter valued at approximately $32,730,000.

Kymera Therapeutics Trading Up 1.6%

Shares of KYMR stock opened at $115.77 on Friday. The firm has a fifty day moving average price of $93.52 and a 200 day moving average price of $85.37. The company has a market cap of $9.52 billion, a P/E ratio of -32.43 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the prior year, the company posted ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% compared to the same quarter last year. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,644,113 shares of company stock valued at $390,820,176. 15.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Truist Financial boosted their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. BTIG Research reiterated a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Finally, Bank of America raised their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Twenty investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.64.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.